Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9214047 | 0.98 | TUBB4A (0.38) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5478180 | 0.77 | HPGD (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6627821 | 0.74 | MEN1 (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3576791 | 0.69 | — | — | |
| SCHEMBL21469888 | 0.66 | SIRT2 (0.45) | L3MBTL1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL11186708 | 0.66 | — | — | |
| SCHEMBL10517955 | 0.64 | HTT (0.56) | L3MBTL1LMNAMAPTHPGDHTT | |
| Diphenylsulfane SCHEMBL451796 | 0.64 | HPGD (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Diphenylsulfane SCHEMBL451795 | 0.64 | HPGD (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Diphenylsulfane SCHEMBL31466756 | 0.64 | HPGD (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1453513-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122018-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| US-20040006087-A1 | Method of treating cancer using FPT inhibitors and antineoplastic agents | SCHERING CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20030229099-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2003-12-11 | — | — | US | disclosed |
| WO-2003047586-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1313725-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2002-12-26 | — | — | US | disclosed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006087-A1 | Method of treating cancer using FPT inhibitors and antineoplastic agents | NNT, FNTB, NNMT | TUBB4A 724/4885TUBB 799/4885TUBA3C 2279/4885 |
| US-20030229099-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | FNTA, FNTB, ACAT2 | TUBB4A 752/4885TUBB 902/4885TUBA3C 1150/4885 |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | FNTB, FNTA, PTAR1 | TUBB4A 1333/4885TUBB 1243/4885TUBA3C 2182/4885 |
| US-20040122018-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | FNTA, FNTB, ACAT2 | TUBB4A 697/4885TUBB 854/4885TUBA3C 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.